A citation-based method for searching scientific literature

Rachel M A Linger, Amy K Keating, H Shelton Earp, Douglas K Graham. Adv Cancer Res 2008
Times Cited: 492







List of co-cited articles
830 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer.
Douglas K Graham, Deborah DeRyckere, Kurtis D Davies, H Shelton Earp. Nat Rev Cancer 2014
413
31

Biology of the TAM receptors.
Greg Lemke. Cold Spring Harb Perspect Biol 2013
342
24

Immunobiology of the TAM receptors.
Greg Lemke, Carla V Rothlin. Nat Rev Immunol 2008
569
22


TAM receptors are pleiotropic inhibitors of the innate immune response.
Carla V Rothlin, Sourav Ghosh, Elina I Zuniga, Michael B A Oldstone, Greg Lemke. Cell 2007
705
20

R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer.
Sacha J Holland, Alison Pan, Christian Franci, Yuanming Hu, Betty Chang, Weiqun Li, Matt Duan, Allan Torneros, Jiaxin Yu, Thilo J Heckrodt,[...]. Cancer Res 2010
360
20

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.
Zhenfeng Zhang, Jae Cheol Lee, Luping Lin, Victor Olivas, Valerie Au, Thomas LaFramboise, Mohamed Abdel-Rahman, Xiaoqi Wang, Alan D Levine, Jin Kyung Rho,[...]. Nat Genet 2012
867
19

The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells.
Magdalena Paolino, Axel Choidas, Stephanie Wallner, Blanka Pranjic, Iris Uribesalgo, Stefanie Loeser, Amanda M Jamieson, Wallace Y Langdon, Fumiyo Ikeda, Juan Pablo Fededa,[...]. Nature 2014
291
18


axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase.
J P O'Bryan, R A Frye, P C Cogswell, A Neubauer, B Kitch, C Prokop, R Espinosa, M M Le Beau, H S Earp, E T Liu. Mol Cell Biol 1991
627
18

The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases.
T N Stitt, G Conn, M Gore, C Lai, J Bruno, C Radziejewski, K Mattsson, J Fisher, D R Gies, P F Jones. Cell 1995
589
18

Receptor tyrosine kinases, TYRO3, AXL, and MER, demonstrate distinct patterns and complex regulation of ligand-induced activation.
Wen-I Tsou, Khanh-Quynh N Nguyen, Daniel A Calarese, Scott J Garforth, Anita L Antes, Sergey V Smirnov, Steve C Almo, Raymond B Birge, Sergei V Kotenko. J Biol Chem 2014
145
16


Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer.
R M A Linger, R A Cohen, C T Cummings, S Sather, J Migdall-Wilson, D H G Middleton, X Lu, A E Barón, W A Franklin, D T Merrick,[...]. Oncogene 2013
142
14

Differential TAM receptor-ligand-phospholipid interactions delimit differential TAM bioactivities.
Erin D Lew, Jennifer Oh, Patrick G Burrola, Irit Lax, Anna Zagórska, Paqui G Través, Joseph Schlessinger, Greg Lemke. Elife 2014
165
14

TAM receptors, Gas6, and protein S: roles in inflammation and hemostasis.
Jonathan H M van der Meer, Tom van der Poll, Cornelis van 't Veer. Blood 2014
180
14

Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival.
Christine Gjerdrum, Crina Tiron, Torill Høiby, Ingunn Stefansson, Hallvard Haugen, Tone Sandal, Karin Collett, Shan Li, Emmet McCormack, Bjørn Tore Gjertsen,[...]. Proc Natl Acad Sci U S A 2010
409
13

AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective.
Samuel H Myers, Valerie G Brunton, Asier Unciti-Broceta. J Med Chem 2016
122
13

An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.
Lauren Averett Byers, Lixia Diao, Jing Wang, Pierre Saintigny, Luc Girard, Michael Peyton, Li Shen, Youhong Fan, Uma Giri, Praveen K Tumula,[...]. Clin Cancer Res 2013
675
13

Tyro-3 family receptors are essential regulators of mammalian spermatogenesis.
Q Lu, M Gore, Q Zhang, T Camenisch, S Boast, F Casagranda, C Lai, M K Skinner, R Klein, G K Matsushima,[...]. Nature 1999
376
13

Expression of axl in lung adenocarcinoma and correlation with tumor progression.
Yi-Shing Shieh, Chiung-Ya Lai, Yu-Rung Kao, Shine-Gwo Shiah, Yi-Wen Chu, Herng-Sheng Lee, Cheng-Wen Wu. Neoplasia 2005
198
12

Macrophages and dendritic cells use different Axl/Mertk/Tyro3 receptors in clearance of apoptotic cells.
Heather M Seitz, Todd D Camenisch, Greg Lemke, H Shelton Earp, Glenn K Matsushima. J Immunol 2007
274
12

Diversification of TAM receptor tyrosine kinase function.
Anna Zagórska, Paqui G Través, Erin D Lew, Ian Dransfield, Greg Lemke. Nat Immunol 2014
254
12

Intracellular signaling of the Ufo/Axl receptor tyrosine kinase is mediated mainly by a multi-substrate docking-site.
J Braunger, L Schleithoff, A S Schulz, H Kessler, R Lammers, A Ullrich, C R Bartram, J W Janssen. Oncogene 1997
126
12

AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells.
Hirokazu Taniguchi, Tadaaki Yamada, Rong Wang, Keiko Tanimura, Yuta Adachi, Akihiro Nishiyama, Azusa Tanimoto, Shinji Takeuchi, Luiz H Araujo, Mariana Boroni,[...]. Nat Commun 2019
144
11

Small-Molecule Inhibition of Axl Targets Tumor Immune Suppression and Enhances Chemotherapy in Pancreatic Cancer.
Kathleen F Ludwig, Wenting Du, Noah B Sorrelle, Katarzyna Wnuk-Lipinska, Mary Topalovski, Jason E Toombs, Victoria H Cruz, Shinichi Yabuuchi, N V Rajeshkumar, Anirban Maitra,[...]. Cancer Res 2018
84
13

AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.
Moshe Elkabets, Evangelos Pazarentzos, Dejan Juric, Qing Sheng, Raphael A Pelossof, Samuel Brook, Ana Oaknin Benzaken, Jordi Rodon, Natasha Morse, Jenny Jiacheng Yan,[...]. Cancer Cell 2015
217
11

Axl as a mediator of cellular growth and survival.
Haley Axelrod, Kenneth J Pienta. Oncotarget 2014
117
11

Phosphatidylserine Sensing by TAM Receptors Regulates AKT-Dependent Chemoresistance and PD-L1 Expression.
Canan Kasikara, Sushil Kumar, Stanley Kimani, Wen-I Tsou, Ke Geng, Viralkumar Davra, Ganapathy Sriram, Connor Devoe, Khanh-Quynh N Nguyen, Anita Antes,[...]. Mol Cancer Res 2017
76
14

Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6.
B C Varnum, C Young, G Elliott, A Garcia, T D Bartley, Y W Fridell, R W Hunt, G Trail, C Clogston, R J Toso. Nature 1995
394
10

Pan-TAM Tyrosine Kinase Inhibitor BMS-777607 Enhances Anti-PD-1 mAb Efficacy in a Murine Model of Triple-Negative Breast Cancer.
Canan Kasikara, Viralkumar Davra, David Calianese, Ke Geng, Thomas E Spires, Michael Quigley, Michael Wichroski, Ganapathy Sriram, Lucia Suarez-Lopez, Michael B Yaffe,[...]. Cancer Res 2019
51
19


Giving AXL the axe: targeting AXL in human malignancy.
Carl M Gay, Kavitha Balaji, Lauren Averett Byers. Br J Cancer 2017
174
10

AXL is an essential factor and therapeutic target for metastatic ovarian cancer.
Erinn B Rankin, Katherine C Fuh, Tiffany E Taylor, Adam J Krieg, Margaret Musser, Jenny Yuan, Kevin Wei, Calvin J Kuo, Teri A Longacre, Amato J Giaccia. Cancer Res 2010
158
10

MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis.
Rebecca S Cook, Kristen M Jacobsen, Anne M Wofford, Deborah DeRyckere, Jamie Stanford, Anne L Prieto, Elizabeth Redente, Melissa Sandahl, Debra M Hunter, Karen E Strunk,[...]. J Clin Invest 2013
112
10

Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis.
Y Li, X Ye, C Tan, J-A Hongo, J Zha, J Liu, D Kallop, M J C Ludlam, L Pei. Oncogene 2009
208
10

MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents.
Nellie K McDaniel, Christopher T Cummings, Mari Iida, Justus Hülse, Hannah E Pearson, Eleana Vasileiadi, Rebecca E Parker, Rachel A Orbuch, Olivia J Ondracek, Noah B Welke,[...]. Mol Cancer Ther 2018
27
37

Phagocytosis and clearance of apoptotic cells is mediated by MER.
R S Scott, E J McMahon, S M Pop, E A Reap, R Caricchio, P L Cohen, H S Earp, G K Matsushima. Nature 2001
864
10

TAM receptors regulate multiple features of microglial physiology.
Lawrence Fourgeaud, Paqui G Través, Yusuf Tufail, Humberto Leal-Bailey, Erin D Lew, Patrick G Burrola, Perri Callaway, Anna Zagórska, Carla V Rothlin, Axel Nimmerjahn,[...]. Nature 2016
318
10

Structural basis for Gas6-Axl signalling.
Takako Sasaki, Pjotr G Knyazev, Naomi J Clout, Yuri Cheburkin, Walter Göhring, Axel Ullrich, Rupert Timpl, Erhard Hohenester. EMBO J 2006
179
10


Gas6/Axl Signaling Pathway in the Tumor Immune Microenvironment.
Mai Tanaka, Dietmar W Siemann. Cancers (Basel) 2020
37
27

Reprogramming the immunological microenvironment through radiation and targeting Axl.
Todd A Aguilera, Marjan Rafat, Laura Castellini, Hussein Shehade, Mihalis S Kariolis, Angela Bik-Yu Hui, Henning Stehr, Rie von Eyben, Dadi Jiang, Lesley G Ellies,[...]. Nat Commun 2016
104
9

AXL mediates resistance to cetuximab therapy.
Toni M Brand, Mari Iida, Andrew P Stein, Kelsey L Corrigan, Cara M Braverman, Neha Luthar, Mahmoud Toulany, Parkash S Gill, Ravi Salgia, Randall J Kimple,[...]. Cancer Res 2014
132
9

Activation of the Receptor Tyrosine Kinase AXL Regulates the Immune Microenvironment in Glioblastoma.
Hirokazu Sadahiro, Kyung-Don Kang, Justin T Gibson, Mutsuko Minata, Hai Yu, Junfeng Shi, Rishi Chhipa, Zhihong Chen, Songjian Lu, Yannick Simoni,[...]. Cancer Res 2018
81
11

Malignant cells fuel tumor growth by educating infiltrating leukocytes to produce the mitogen Gas6.
Sonja Loges, Thomas Schmidt, Marc Tjwa, Katie van Geyte, Dirk Lievens, Esther Lutgens, Davy Vanhoutte, Delphine Borgel, Stephane Plaisance, Marc Hoylaerts,[...]. Blood 2010
121
9

The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression.
Marie-Anne Goyette, Stéphanie Duhamel, Léo Aubert, Ariane Pelletier, Paul Savage, Marie-Pier Thibault, Radia Marie Johnson, Peter Carmeliet, Mark Basik, Louis Gaboury,[...]. Cell Rep 2018
78
11

Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy.
W Leconet, C Larbouret, T Chardès, G Thomas, M Neiveyans, M Busson, M Jarlier, N Radosevic-Robin, M Pugnière, F Bernex,[...]. Oncogene 2014
70
12

Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib.
Keith M Giles, Felicity C Kalinowski, Patrick A Candy, Michael R Epis, Priscilla M Zhang, Andrew D Redfern, Lisa M Stuart, Gregory J Goodall, Peter J Leedman. Mol Cancer Ther 2013
116
9

Cloning and mRNA expression analysis of a novel human protooncogene, c-mer.
D K Graham, T L Dawson, D L Mullaney, H R Snodgrass, H S Earp. Cell Growth Differ 1994
262
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.